<DOC>
	<DOCNO>NCT01276548</DOCNO>
	<brief_summary>The purpose study Evaluate Efficacy Safety Combination Therapy Genexol®-PM Plus Carboplatin® Compared Genexol® Plus Carboplatin® Firstline Treatment Subjects With Ovarian Cancer .</brief_summary>
	<brief_title>A Trial Evaluate Efficacy Safety Combination Therapy Genexol®-PM Plus Carboplatin® Compared Genexol® Plus Carboplatin® Firstline Treatment Subjects With Ovarian Cancer</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>1 . Subjects age 18 year old 2 . Subjects whose write informed consent obtain comply local regulatory requirement prior participation trial 3 . Subjects histologically cytologically confirm unresectable metastatic epithelial cancer exocrine pancreas . Highquality contrastenhanced CT scan require evaluate resectability . Measurable disease require . 1 . Subjects receive prior radiation therapy ( XRT ) pancreatic cancer unless progression document XRT 6 week elapse completion XRT start trial medication . 2 . Subjects systemic treatment chemotherapy immunotherapy , pancreatic cancer . However , prior use chemotherapy , e.g . 5FU capecitabine , radiation sensitization allow . If gemcitabine give adjuvant setting , subject relapse cancer 6 month complete last dose gemcitabine participate trial . 3 . Subjects major surgery within 2 week prior screening/baseline visit</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2011</verification_date>
</DOC>